Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q3 2019 · 10-Q
Revenue$2.38M$2.38M+3.4% vs Q3 2018 Net Income-$700.95K-$700.95KN/M vs Q3 2018 EPS Diluted-$0.02-$0.02N/M vs Q3 2018 Gross Profit$372,759−27.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Operating Cash Flowderived$471,878−46.6% Free Cash Flowderived$459,677−47.8% Margins · derivedGross margin15.7%−6.6 pt vs Q3 2018
Operating margin-27.1%+56.9 pt vs Q3 2018
Net margin-29.5%+51.3 pt vs Q3 2018
ended Sep 30, 2019 · filed Nov 14, 2019 · 45 d after period end